Nationally Recognized Leader in Neuroendocrine and Endocrine Tumors Joins the TGH Cancer Institute

Dr. Boris Naraev specializes in the treatment and research of patients with gastrointestinal, neuroendocrine and endocrine cancers.

TAMPA, Fla., Feb. 12, 2025 /PRNewswire/ — Tampa General Hospital (TGH) today announced that Dr. Boris Naraev, a medical oncologist specializing in caring for patients living with gastrointestinal, neuroendocrine and endocrine tumors, has joined the TGH Cancer Institute. In addition, he has been appointed as associate professor in the Department of Internal Medicine at the USF Health Morsani College of Medicine.

Bringing Naraev to the academic health system’s Cancer Institute will significantly aid the fight against difficult-to-treat cancers in the Tampa Bay area and beyond, said Dr. Eduardo M. Sotomayor, vice president and executive director of the TGH Cancer Institute.

“The strength of my enthusiasm for Dr. Naraev is based on his prestigious academic credentials and his clinical research accomplishments to date in the highly specialized area of neuroendocrine and endocrine cancers, where he is a recognized national leader,” Sotomayor said.

Naraev was previously with the Anderson Family Cancer Institute at the Jupiter Medical Center in Jupiter, Florida, where he served as leader of the Gastrointestinal, Neuroendocrine and Rare Cancers Program. He also worked at Banner MD Anderson Cancer Center in Phoenix, where he helped develop and lead one of the largest neuroendocrine cancer programs in the southwestern United States, while serving as an adjunct assistant professor with the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

He earned a Doctor of Medicine degree, Summa Cum Laude, in 1994 and a Doctor of Philosophy in Medical Sciences in 2001 from the Orenburg State Medical Academy in Orenburg, Russia.

Dr. Noman Ashraf, a medical oncologist and physician leader at the TGH Cancer Institute, works alongside Naraev in caring for patients with solid tumors. “Dr. Naraev’s accomplishments in clinical care, research and education make him an incredibly valuable asset to our team,” Ashraf said. “I’m confident in his ability to provide our patients cutting-edge treatment and access to novel clinical trials.”

Endocrine tumors can arise from any endocrine cell within hormone-producing glands and organs such as the thyroid, adrenal, parathyroid and pituitary glands, as well as the hypothalamus and pancreas. Neuroendocrine tumors are rare and can develop only from neuroendocrine cells, which share similar characteristics with nerve and hormone-producing cells.

“Since joining the TGH Cancer Institute, Dr. Naraev has become the driving force in bringing innovative and potentially practice-changing clinical trials to our institution to help patients with neuroendocrine, endocrine and gastrointestinal cancers,” said Dr. Richard Tuli, deputy director of the TGH Cancer Institute and professor and chair of the Department of Radiation Oncology at the USF Health Morsani College of Medicine. As a nationally recognized expert on radiopharmaceutical therapy, Naraev brings his knowledge and expertise to the Cancer Institute. “We’re very fortunate he’s part of the team,” Tuli said.

For Naraev, the TGH Cancer Institute, its people and approach to treating patients won him over immediately. “To be part of one of the nation’s best medical centers is something I’ve always dreamed of,” he said. “I know I’ll do my best work here and translating that energy to our patients couldn’t make me more proud, both as a doctor and as a human being.”

“The introduction of Dr. Naraev to the Cancer Institute is another great stride toward Tampa General’s goal in becoming the nation’s best health care center,” says Dr. Abraham Schwarzberg, executive vice president, chief of Oncology, president of the Tampa General Provider Network, Tampa General and co-vice president of Clinical and Translational Research, TGH-USF Health Office of Clinical Research. “We are thrilled to have a renowned educator, researcher and exceptional physician join us in our efforts to deliver world-class care to all of our patients.”

One of the few Florida cancer centers backed by academic medicine, the TGH Cancer Institute ranks among the nation’s top 50 cancer centers in U.S. News & World Report’s 2024-2025 Best Hospitals and No. 3 in the state. The institute provides comprehensive care via groundbreaking therapies, advanced diagnostic imaging tools and a highly coordinated, interdisciplinary approach to world-class patient care. It is certified by the American College of Surgeons’ Commission on Cancer Accreditation and by the American Society of Clinical Oncology (ASCO) for meeting the strict standards required by the society’s Quality Oncology Practice Initiative (QOPI®) program and has been named among America’s Best Cancer Hospitals by Newsweek. For more information about the TGH Cancer Institute, visit www.tgh.org/cancer.

ABOUT TAMPA GENERAL HOSPITAL
Tampa General Hospital, a 981-bed, not-for-profit, academic health system, is one of the largest hospitals in America and delivers world-class care as the region’s only center for Level l trauma and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News & World Report’s 2024-2025 Best Hospitals, with two medical specialties ranking among the top 20 in the nation and eight medical specialties ranking among the top 50 best hospital programs in the United States. Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list. The academic health system’s commitment to growing and developing its team members is recognized by three prestigious Forbes magazine rankings – in the top 100 nationally in the 2024 America’s Best Large Employers, the top 50 in Florida in the 2024 America’s Best Employers by State and the 2023 America’s Best Employers for Women. Tampa General is the safety net hospital for the region, caring for everyone regardless of their ability to pay, and in fiscal year 2022, provided a net community benefit of approximately $240.3 million in the form of health care for underinsured patients, community education, and financial support to community health organizations in Tampa Bay. It was the nation’s busiest adult solid organ transplant center in 2024 and is the primary teaching hospital for the USF Health Morsani College of Medicine. With five medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center, and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It also is home to the Muma Children’s Hospital at TGH, the Jennifer Leigh Muma 82-bed neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital’s footprint includes TGH North, which is comprised of three hospitals and several outpatient locations in Citrus and Hernando counties, 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, two TGH Outpatient Centers, TGH Virtual Health, and 20 TGH Imaging outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents also receive world-class care from the TGH Urgent Care powered by the Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital (tgh.org). As one of the largest hospitals in the country, Tampa General Hospital is the first in Florida to partner with GE Healthcare and open a clinical command center that provides real-time situational awareness to improve and better coordinate patient care at a lower cost. For more information, go to www.tgh.org.

Media Contact: Beth Hardy, APR
Assistant Manager
Publications & Physician Communications
(727) 510-6363 (cell)
[email protected]

SOURCE Tampa General Hospital


Go to Source